Showing results (491-500 of 644) with videos related to

Sort By:
Pageof 65
Journal of Viral Hepatitis|October 31, 2009
Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West AfricaM E Mendy, T Welzel, O A Lesi, et al.
Circulation|June 25, 2003
Staphylococcus aureus bacteremia after median sternotomy: clinical utility of blood culture results in the identification of postoperative mediastinitisVance G Fowler, Keith S Kaye, David L Simel, et al.
International Journal of Obesity (2005)|December 6, 2017
Adipose tissue mitochondrial capacity associates with long-term weight loss successR Jokinen, R Rinnankoski-Tuikka, S Kaye, et al.
Experimental Eye Research|December 18, 2008
A transcriptomic analysis of the EK1.Br strain of human fibroblastoid keratocytes: the effects of growth, quiescence and senescenceDavid Kipling, Dawn L Jones, S Kaye Smith, et al.
Frontiers in Pharmacology|October 22, 2019
Synergistic Combination of Polymyxin B and Enrofloxacin Induced Metabolic Perturbations in Extensive Drug-Resistant Pseudomonas aeruginosaYu-Wei Lin, Mei-Ling Han, Jinxin Zhao, et al.
The Lancet. Infectious Diseases|December 3, 2014
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensusRoger L Nation, Jian Li, Otto Cars, et al.
Antimicrobial Agents and Chemotherapy|October 9, 2013
Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomesTeena Chopra, Dror Marchaim, Reda A Awali, et al.
The Lancet. Infectious Diseases|October 15, 2020
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trialRichard G Wunderink, Yuko Matsunaga, Mari Ariyasu, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2017
Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activityJustin R Lenhard, Visanu Thamlikitkul, Fernanda P Silveira, et al.
The Lancet. Infectious Diseases|May 14, 2023
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)Keith S Kaye, Andrew F Shorr, Richard G Wunderink, et al.
Pageof 65